271. Ankylosing spondylitis Clinical trials / Disease details
Clinical trials : 563 / Drugs : 372 - (DrugBank : 72) / Drug target genes : 41 - Drug target pathways : 145
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02893254 (ClinicalTrials.gov) | September 22, 2016 | 29/8/2016 | Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis | A Multicenter, Randomized, Double-blind, Parallel-controlled Phase 3 Study Evaluating the Efficacy and Safety of Recombinant Human Monoclonal Antibody Against Human Tumor Necrosis Factor-a (IBI303) Compared to Adalimumab in Patients With Active Ankylosing Spondylitis | AS | Drug: IBI303;Drug: Adalimumab | Innovent Biologics (Suzhou) Co. Ltd. | NULL | Completed | 18 Years | 65 Years | All | 438 | Phase 3 | NULL |